Day 2 :
Engi-Medco Solutions (SEMCO) & Amplexi-LLC, USA
Keynote: A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology Using Natural Tumor Sensitizers for Treatment of Triple Negative Breast Cancer Patients
Time : 10:00-10:45
Raghu Pandurangi started his scientific career Ph.D. in spectroscopy followed by post-doctoral training at Radiology and Internal medicine, University of Missouri, Columbia where he remained as a faculty researching on radiopharmaceuticals of cancer and cardiovascular diseases. His patent/grant on Angiotensin II imaging for the prediction of heart failure project fetched him principle investigator position in Shering AG, Germany where he directed drug development program involving in 2 FDA approved drugs (AccuTect and NeoTect). He was a team leader at Mallinckrodt directing apoptosis imaging in 2004. He became an entrepreneur in 2013 inventing AAAPT technology for improving FDA approved drugs. Currently, he is the Founder, President and CSO of Sci-Engi-Medco Solutions (SEMCO) and Amplexi-LLC, recipient of several grants. His extra curriculum activities include VP duties for non-profit organizations Anu-Rag School of Music and Sangeetha. He is also percussionist playing Indian drums (Tabla) for his school passionating Music therapy for palliation of pain
Statement of the Problem: Cancer cells have inherent ability to circumvent intervention irrespective of the nature of intervention by desensitizing themselves through a) activating survival pathways (e.g. NF-kB, PARP) and downregulating cell death pathways (e.g. CD95, ASK1) simultaneously. The situation is worse for triple negative breast cancer (TNBC) patients who have no option except non-specific chemotherapy, despite high off-target toxicity. No targeted therapy is approved for TNBC treatment since TNBC lack biomarkers (e.g. PR, ER and HER2 negative) for which drugs are designed. This puts TNBC patients on an enormous risk for survival. The purpose of this study is to make FDA approved drugs better using AAAPT technology. Methodology and Theoretical Orientation: The proprietary AAAPT technology-based drug design utilizes natural tumor sensitizers derived from plants and/or human proteins and are targeted to cancer cells by using tumor specific biomarkers (e.g. Cathepsin B, SSTR2). The idea here is to revamp or inhibit specific signal pathways identified in the desensitization process. Findings: The leading AAAPT drug molecules activated CD95 cell death pathway and inhibited NF-kB and PARP simultaneously and selectively in cancer stem cells (CSCs) and in drug resistant tumor cells. The sensitizing potential of AAAPT drugs is reflected in the reduction of IC-50 of several front-line chemotherapeutics (e.g. doxorubicin, paclitaxel, gemcitabine) by 10-15 times. As a result, the combination of AAAPT with chemotherapy achieved tumor regression in an in vivo xenograft TNBC tumor model at a much lower dose of chemotherapy and reduced dose resulted cardiotoxicity. Conclusion and Significance: AAAPT synergizes with chemotherapy to make it clinically effective by reducing the side effects. The broader significance of AAAPT is that it can, potentially be used as a neoadjuvant to different therapeutic modalities including chemotherapy, radiation therapy, immunotherapy and radionuclide therapy and clinically translatable for a better management of cancer patients.
- Innovative Therapeutic Approaches in Breast Cancer | Breast cancer Surgery Choices | Prevention of Breast cancer | Breast Reconstruction
University of Babylon, IRAQ
Title: Correlation of Reduced Glutathione with Brest Cancer Using High Performance Liquid Chromatography
Time : 10:45-11:30
Mufeed J. Ewadh has his expertise in many fields of biochemistry research in his institute dealing with health problem, herbal extraction, alternative medicine .He participated in many international and local conferences and workshops which deal with improvement of biochemical research to increase people awareness about its role .He participated in post doctorate course in Marburg University (Germany) on 2005 ,and he participated in electrophoresis workshop in japan for two weeks as well as in biochemical workshop in Leipzig (Germany) / 2016.His postgraduate supervision deals with many graduate students (M.Sc. and Ph.D.) which focus on publishing more than 140 papers in different local and international journals. His interest in publishing research paper made his institute to nominate him as the best professor for two years (2003),(2009) .He is chief in editor of most famous journal in Iraq (Medical Journal of Babylon ) and he got many rewards during his scientific life.
Breast cancer (BC) is a type of malignancy appeared in breast tissue, occurs in both premenopausal and also in postmenopausal women’s. Glutathione (GSH) is a tripeptide that is found intracellularly in high concentration, being the most abundant low molecular mass thiol .A total of 80 patient with (BC) divided in two groups, first group (n=40) women with breast cancer without chemotherapy, second group (n= 40 ) women with breast cancer with chemotherapy. The control group (n= 40) apparently healthy women’s matched with patient group. Women with (BC) have a significant lower serum level of (GSH) than those who are not diseased and even than those who received chemotherapy (p˂ 0.05) So, this lead to a conclusion that; breast cancer women have low level of GSH and increased upon administration of chemotherapy. The objective of this study is to assess GSH status in women’s BC receiving chemotherapy treatment.
Sichuan Provincial People’s Hospital, China
Jun Luo has devoted himself in the work and research of Ultrasonic Contrast and Interventional Ultrasound after the graduation from The West China College of Medicine of Sichuan University. At present, he is holding the position of Secretary of Ultrasound Department, Standardized training base for Ultrasonic Medical residents, Secretary of Imaging and Nuclear Medicine Teaching and Research section (Ultrasonic Medicine Section) in Medical School Attached UESTC
Sentinel lymph node(SLN) location and biopsy was designed to minimize side effects of axillary dissection with equivalent outcomes. This prospective study is to evaluate the feasibility of periareolar injection of contrast agent SonoVueTM followed by ultrasound(US) for identification and localization of SLN in breast cancer patients with clinically negative node. From July, 2017 through January, 2018, 130 women were enrolled in the study。SonoVueTM was injected periareolarly and followed by US to detect enhanced sentinel lymphatic channels(SLCs) and SLNs 1minute later after massage. The patients were randomly divided into two groups to locate the first enhanced SLN: 1) US-guided marker placing; 2) US-guided nano-carbon(N) injection into SLN. Compare the number of SLNs detect by CEUS with blue dye(B) or N mapping, and the coincidence rate of the first SLN located by CEUS with those traced by the B and N. Lymph nodes that were dark, blue, with marker or clinically positive were considered sentinel nodes and to be biopsied。121 of 130 patients with breast cancer patients injected with ultrasound contrast agents had detected a total of 254 enhanced SLNs (range 1-5, 2.1 + 1.05) compared with total of 342 SLNs (range 1-5, 2.83 + 1.10) mapping with B or N. 42 of 45 first SLNs located with marker matched with first SLNs stained with N (42/45,93.33%); 70 of 76 first SLNs using N injecting directly guided by CEUS matched with first SLNs stained with B (70/76,92.1%). In another 9 cases without enhanced SLN, 4 of them didn’t stained with N or B, and 5 were stained. The sensitivity of SLNs detection by CEUS was 96.03% (121/126), and the accuracy of locating the first SLN was 92.56% (112/121).
University of the Witwatersrand, South Africa
Sourav Taru Saha is a PhD. student working on Breast cancer at the University of the Witwatersrand. The research group’s main focus is the link between Cholesterol and Breast cancer. Till now, his research has shown promising results and in 2018 the concept would be tested in vivo.
Cancer cells have an increased need for cholesterol, which is required for cell membrane integrity. Cholesterol accumulation has been described in various malignancies including breast cancer. Cholesterol has also been known to be the precursor of estrogen and vitamin D, both of which play a key role in the histology of breast cancer. Thus, depleting the cholesterol levels in cancer cells is a proposed innovative strategy to treat cancer. Therefore, novel cholesterol-depleting compounds are currently being investigated. KS-01 is a cyclic amylose oligomer composed of glucose units. It solubilizes the cholesterol and is proven to be toxicologically benign in humans. This led us to hypothesize that it might deplete cholesterol from cancer cells and may prove to be a clinically useful compound. Our work provides preliminary experimental evidences to support this hypothesis. We identified the potency of KS-01 in vitro against two breast cancer cell lines: MCF-7 (Estrogen positive, ER+), MDA-MB-231(Estrogen negative, ER-) and compared the results against two normal cell lines: MRC-5 (Normal Human Lung Fibroblasts) and HEK-293 (Normal human embryonic kidney cells) using cytotoxic, apoptosis and cholesterol based assays. KS-01 treatment reduced intracellular cholesterol resulting in significant breast cancer cell growth inhibition through apoptosis. The results hold true for both ER+ and ER-. These data suggest that KS-01 can prevent cholesterol accumulation in breast cancer cells and is a promising new anticancer agent.
Sumeyya Azam is a Clinical Research Officer in Shaukat Khanum Memorial Cancer Hospital & Research Centre, Pakistan. She received her MBBS and MS (Obstetrics and Gynecology) degrees from Xinjiang Medical University, China in 2012 and 2015, respectively, and awarded with ‘Honorary Credential. She has done ICH GCP trainings by ROCHE/GENENTECH, Singapore and LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE and got certified. She is also GDP certified. Currently, she is a part of three international Clinical trials and basic science research studies. She has published various articles and chapters in International reputed journals and eBooks, respectively, and has been serving as an editorial board member of repute. She got her research abstracts published in national and international conferences’ journals. She has been recognized as “Certified Sentinel of Science Award Recipient” by the Publons Board in 2016.
An epidemic outbreak of breast cancer is the most threatening health issue amongst women globally. Various risk factors are known that lead to the development of breast cancer including emerging obesity trends as one of the most established risk factors for breast cancer that has become a global epidemic. Obesity or high BMI is at the crux of the development of breast cancer. Though a leading public health issue, valuable link between obesity and breast cancer has become the subject of expound research. This brief review overviews this critical issue and sheds light on the obesity’s worst impact on the development and progression of breast cancer, which can provide awareness and cognizance regarding the maintenance of healthy body weight. The relevant literature was collected by searching PubMed and Google Scholar. Over the last decade, various epidemiological studies investigated a close association between excess adiposity and development of breast cancer. Obesity, itself is a disorder involving accumulation of excess body fat and thence, increasing the risk of developing neoplastic lesions. The exponential rise in the number of obese women is markedly playing a major role in the increased incidence of breast cancer worldwide especially among post-menopausal women and is an early warning risk for pre-neoplastic lesions. By changing the modifiable lifestyle factors including physical activity and healthy eating with minimal animal fat consumption we can compete with the huge burden of obesity and its impact on incidence and prognosis of breast cancer.
Mashhad Azad University,Iran
Will be updated soon...
The aim of this study was to assessment the effectiveness of cognitive-behavioral therapy with a spiritual approach to women's resilience suffering from breast cancer. This research is a semi-experimental design with pretest-post-test design. The statistical population included all women with breast cancer referring to the Imam Reza clinic in Mashhad in 2017.
Experimental group (n=12) control group (n=12) were chosen by Convenience sampling method, and the experimental group was educated by cognitive-behavioral therapy with a spiritual approach for 10 session which takes 70-minute. The Conver and Davidson resilience Questionnaire was used (2003).
The results showed that cognitive-behavioral therapy with spiritual approach is effective on resilience and its components in women with breast cancer.
It seems that cognitive-behavioral therapy with a spiritual approach can improve resilience and its components in women with breast cancer.
Will be updated soon..
Breast cancer is the most common cancer in women both in the developed and less developed world. Breast cancer survival rates vary greatly worldwide, ranging from 80% or over in North America, Sweden and Japan to around 60% in middle-income countries and below 40% in low-income countries. The low survival rates in less developed countries can be explained mainly by the lack of early detection programs, resulting in a high proportion of women presenting with late-stage disease, as well as by the lack of adequate diagnosis and treatment facilities. The menace of breast cancer has not spared Pakistan with its incidence reaching up to almost 35,000/100,000. 30.8% of all cancer deaths in Pakistan are due to breast cancer. Given that Pakistan is a low resource setting, we designed a screening program based on examination for the detection of breast cancer.
The study was piloted in the rural area of Rehri-goth. Pre-medical volunteer students were trained on breast self-examination. The volunteers went door to door creating awareness in the community regarding the danger signs of breast cancer and the importance of self-examination. All participants who identified any danger sign were called to the outreach centre of AKU for clinical breast examination followed by diagnostic mammography.
In a 7 days period, 526 houses were reached and 93 women were educated. 18 women were examined by a surgeon in the outreach centre. 2 women were filtered for a diagnostic mammography. The potential participants were taken to Karachi for mammography. One of them had Paget’s disease. The other woman was diagnosed with stage II breast cancer.
Although mammography has been established as the gold standard for screening breast cancer in the community, yet, in a low resource setting like Pakistan, breast self examination followed by clinical breast examination can serve as a useful tool.